We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

91 hedge funds and large institutions have $87.5M invested in Arbutus Biopharma in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.78% more ownership

Funds ownership: 27.21% → 29.99% (+2.8%)

1% more capital invested

Capital invested by funds: $86.5M → $87.5M (+$1.04M)

3% less funds holding

Funds holding: 94 → 91 (-3)

12% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 25

14% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 22

44% less call options, than puts

Call options by funds: $2.76M | Put options by funds: $4.95M

Holders
91
Holders Change
-3
Holders Change %
-3.19%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
22
Reduced
25
Closed
22
Calls
$2.76M
Puts
$4.95M
Net Calls
-$2.19M
Net Calls Change
-$573K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$11.6M
2
State Street
State Street
Massachusetts
+$3.41M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$2.8M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.33M
5
Northern Trust
Northern Trust
Illinois
+$1.82M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$3.35M
2
Morgan Stanley
Morgan Stanley
New York
-$2.6M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.81M
4
Millennium Management
Millennium Management
New York
-$1.74M
5
Two Sigma Investments
Two Sigma Investments
New York
-$1.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
JWA
76
JFS Wealth Advisors
Pennsylvania
$3K – – –
Federated Hermes
77
Federated Hermes
Pennsylvania
$3K +$424 +137 +14%
FDCDDQ
78
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.42K – – –
GWM
79
Geneos Wealth Management
Colorado
$2K – – –
HIA
80
Harbor Investment Advisory
Maryland
$2K – – –
PA
81
Parallel Advisors
California
$2K – – –
RG
82
Retirement Group
California
$2K – – –
AF
83
Advisornet Financial
Minnesota
$1K – – –
HI
84
Harbour Investments
Wisconsin
$1K – – –
NFG
85
Next Financial Group
Texas
$1K – – –
TF
86
TimeScale Financial
Massachusetts
$1K – – –
AIG
87
American International Group
New York
$133 +$136K +43,763 New
Renaissance Technologies
88
Renaissance Technologies
New York
– -$3.35M -1,004,500 Closed
Millennium Management
89
Millennium Management
New York
– -$1.74M -523,263 Closed
GCP
90
GSA Capital Partners
United Kingdom
– -$1.03M -309,839 Closed
MWNA
91
Marshall Wace North America
New York
– -$786K -235,951 Closed
PAMU
92
Pictet Asset Management (UK)
United Kingdom
– -$696K -209,129 Closed
KA
93
Kerrisdale Advisers
Florida
– -$693K -208,150 Closed
ECM
94
ExodusPoint Capital Management
New York
– -$533K -160,048 Closed
California Public Employees Retirement System
95
California Public Employees Retirement System
California
– -$409K -122,700 Closed
IC
96
Ikarian Capital
Texas
– -$383K -115,000 Closed
WP
97
Woodline Partners
California
– -$261K -78,339 Closed
PP
98
PDT Partners
New York
– -$241K -72,500 Closed
LP
99
LMR Partners
United Kingdom
– -$140K -42,171 Closed
Squarepoint
100
Squarepoint
New York
– -$100K -29,880 Closed
1 2 3
4
5

ABUS Hedge Fund Activity: Q2 2021 in Review

91 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2021, worth a combined $87.5M — up 1.2% from $86.5M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ABUS and 19 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 22 added.

The largest buyer was BlackRock, adding an estimated $11.6M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $3.35M sold.

  • 91 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2021, down from 94 in Q1 2021.
  • Funds reported $87.5M of Arbutus Biopharma stock for Q2 2021, up 1.2% quarter-over-quarter.
  • 19 funds opened new Arbutus Biopharma positions in Q2 2021 and 22 closed out, a net change of -3 holders.
  • The largest Arbutus Biopharma buyer in Q2 2021 was BlackRock, an estimated $11.6M added.
  • The largest Arbutus Biopharma seller in Q2 2021 was Renaissance Technologies, an estimated $3.35M sold.

Based on aggregated 13F filings for Q2 2021.